Advocacy, Research & Drug Development, Understanding Rare Disease NORD RareInsights® 5 Myths About the ODA
Advocacy, Research & Drug Development Published December 18, 2018 Orphan Drugs in the United States: Exclusivity, Pricing and Treated Populations
Advocacy, Regulatory, Telehealth, Understanding Rare Disease NORD RareInsights® Ensuring Access to Telehealth for Rare Diseases
Advocacy, Research & Drug Development, Understanding Rare Disease NORD RareInsights® Barriers to Rare Disease Diagnosis, Care and Treatment in the US: A 30-Year Comparative Analysis Inforgraphic
Advocacy, Research & Drug Development, Understanding Rare Disease NORD RareInsights® Barriers to Rare Disease Diagnosis, Care and Treatment in the US: A 30-Year Comparative Analysis
Advocacy, Research & Drug Development Orphan Drugs in the United States: Rare Disease Innovation and Cost Trends Through 2019
Advocacy, Regulatory, Research & Drug Development Orphan Drugs in the United States: An Examination of Patents and Orphan Drug Exclusivity
Regulatory, Research & Drug Development Published June 1, 2021 FDA’S Accelerated Approval Pathway: A Rare Disease Perspective
Advocacy, Legislative Advocacy, Rare Disease Advisory Councils (RDAC) Webinar Recording: Your State Just Enacted an RDAC – Now What?
Legislative Advocacy, Rare Disease Advisory Councils (RDAC) Toolkit: Advocating for a Rare Disease Advisory Council in Your State
Understanding Rare Disease Published March 1, 2015 Huntington’s Disease: Emerging Concepts in Diagnosis and Treatment